We have placed cookies on your computer to help make this website better. We use a PIWIK Analytics script which sets performance cookies. More details and information can be found in our cookie policy. Please refer to the privacy statement to adjust your settings for the website analytics tracking by PIWIK (e.g. deny use/opt-out). More info

Confirm

Improving the lives of patients is our mission. We are an ambitious and dynamic business with a healthy innovation-driven pipeline that enables us to build on our core expertise in pain. Strong ongoing partnerships with leading healthcare and development organisations bring our new products to life. This commitment to innovation and thought-leadership means that next generation scientific talent is drawn to us.

Grünenthal. Change is possible.

locations
30

We are present in 30 countries with affiliates in Europe, Latin America and the US.

market presence
100

Our products are sold in more than 100 countries.

employees
5,200

5,200 employees work for our group worldwide.


Please read more about our projects supported by resources of the European Regional Development Fund

... Read More

What we do

As a fully integrated research & development company we bring innovative pain treatments and state-of-the-art technologies to patients.

... Learn more about Grünenthal

Pioneering thinkers

Our passion is innovation. We are driven to seek new solutions for patients with severe diseases and high unmet medical needs – and make these solutions accessible to patients.
... Find out more

Careers

Ready to create a brighter future for our patients?
With us, let your passion and ideas flow and drive innovation to improve our patients’ lives.

... Work with Grünenthal

Featured news & articles

Monica Vazquez
Monica Vazquez
Public_disclosure_Declaration
Master of Pharmaceutical Medicine

Pain Congress

A day in the life of a Medical Science Liaison

Mónica Vazquez is part of the medical department in the Grünenthal Spanish affiliate and works as Medical Science Liaison (MSL). Her work involves interactions with a broad number of stakeholders including doctors, nurses, and medical societies. Her main mission is to use science and educational skills to support better outcomes for patients and better understanding of the disease and patients’ unmet needs.

Author: Kristina Barinka

Public Disclosure Declaration

Grünenthal aims to be in the top 10 for clinical trial transparency

The 2018 update of our Public Disclosure Declaration aligns Grünenthal worldwide with the currently most stringent transparency standard and goes beyond what is legally required or the industry standard. It is another step towards our goal of being one of the top 10 companies for clinical trial transparency.

Author: Christopher Marshallsay

Pharmaceutical Medicine

Making masters

For many years, the University of Duisburg-Essen has engaged in partnerships with representatives from public authorities and industry – including Grünenthal. These partnerships provide young people studying for an MSc in Pharmaceutical Medicine with practical insights from the world of work and help them shape their ideas about the career path they want to follow after graduation.

Author: Mohamed Adib

Graduate program

Developing a diverse skillset

Monique Mendel Ott recently accepted a job as a regulatory professional at Grünenthal – after completing our two-year graduate trainee program. Together with her mentor, Mohamed Adib, she shares insights into her development journey and the new career path she’s now exploring

Author: Janine Bleilevens

12/7/2018

Aachen, Germany, December 7, 2018 – Grünenthal is participating in the PAIN-Vis research initiative and working with the University of Cologne, the Goethe University Frankfurt and Forschungszentrum Jülich [Jülich Research Center] to create a foundation for improvements in pain diagnosis. The basic research project will receive €2.26 million from the European Regional Development Fund and the German federal state of North Rhine-Westphalia over three years from 2017 to 2020 (PAIN-Vis grant ref. EFRE-800975).

12/3/2018

Aachen, Germany, 03 December 2018 – Grünenthal today announced the successful completion of its acquisition of European rights to Nexium and global (ex US and Japan) rights to Vimovo from AstraZeneca for a total consideration of up to US$ 922 m (€ 811 m). “Today is an important day for Grünenthal,” said Gabriel Baertschi, CEO Grünenthal. “This transaction represents a significant step towards our vision of creating a world free of pain for patients. It is also is the biggest single investment in the history of our company. This transaction will double our EBITDA performance and significantly strengthen our leading position in pain management”.

11/14/2018

Aachen, Germany / Morristown, New Jersey, USA, 14 November, 2018 – Grünenthal announced today that it has acquired the US-based pharmaceutical company Averitas Pharma, thereby extending its commercial footprint to the United States. Averitas Pharma will be commercialising the pain patch Qutenza® (8 % capsaicin) for Grünenthal in the US. Grünenthal had only recently acquired the remaining global rights, including the US rights, for the product from Acorda Therapeutics.

11/5/2018

Aachen, Germany, 5 November 2018 – Grünenthal, the science-focused pharmaceutical company based in Germany, announced today that it has acquired additional global commercial rights for the dermal pain patch Qutenza® (8% capsaicin) from Acorda Therapeutics, Inc (USA). Grünenthal is now the sole owner of Qutenza® worldwide, including the US, Latin America, Asia and Australia. Grünenthal had already acquired exclusive commercial rights for Europe, Middle East and Africa in December 2016.

10/30/2018

Aachen, Germany, 30 October 2018 – Grünenthal today announced that it has agreed to acquire AstraZeneca’s European rights to Nexium and the global (ex US and Japan) rights to Vimovo for a total consideration of up to US$ 922 m (€ 811 m). Nexium (esomeprazole) is a proton pump inhibitor (PPI) that helps to reduce the amount of acid produced by the stomach in patients with gastroesophageal reflux conditions and ulcers. It has a number of indications, including the prevention and treatment of gastric ulcers induced by pain-relieving non-steroidal anti-inflammatory drugs (NSAIDs). Vimovo is a fixed-dose combination tablet of naproxen, a pain-relieving non-steroidal anti-inflammatory drug (NSAID) and esomeprazole, the same gastroprotective active ingredient as in Nexium. It is indicated for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients at risk of developing NSAID-associated gastric and/or duodenal ulcers.